Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI87364PMID 27035815PMCID PMC4811110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

  2015cited by this paper
• PCSK9: A Key Modulator of Cardiovascular Health

  2014cited by this paper
• Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.

  2014cited by this paper
• CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.

  2014cited by this paper
• Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

  2014cited by this paper
• Abstract 120: Effects of Anacetrapib Treatment on CETP Metabolism

  2013cited by this paper
• Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

  2013cited by this paper
• Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S]

  2012cited by this paper
• Rationale for cholesteryl ester transfer protein inhibition

  2012cited by this paper
• Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

  2012cited by this paper
• Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

  2011cited by this paper
• Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

  2011influential reference
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet

  2010cited by this paper
• Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

  2010cited by this paper
• A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor*

  2010cited by this paper
• Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

  2010cited by this paper
• LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor

  2009cited by this paper
• Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

  2009cited by this paper
• An efficient method for accommodating potentially underpowered primary endpoints

  2008cited by this paper
• Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.

  2008cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

  2007cited by this paper
• Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans

  2006influential reference
• Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production

  2005cited by this paper
• Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

  2005cited by this paper
• Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion

  2005cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• Use of the false discovery rate for evaluating clinical safety data

  2004cited by this paper
• The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

  2004cited by this paper
• Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain DOI 10.1194/jlr.M200071-JLR200

  2002cited by this paper
• Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study

  2002cited by this paper
• A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

  2000cited by this paper
• Lipoprotein lipase activity and mRNA levels in bovine tissues.

  1998cited by this paper
• Differences in receptor binding of LDL subfractions.

  1996influential reference
• Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma.

  1996cited by this paper
• Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.

  1995cited by this paper
• Plasma cholesteryl ester transfer protein.

  1993cited by this paper
• Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency.

  1991cited by this paper
• Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.

  1990cited by this paper
• Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.

  1988cited by this paper
• Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins.

  1980cited by this paper
• Triglyceride removal from very low density lipoproteins in vivo as a function of their triglyceride content.

  1979cited by this paper
• A stable, radioactive substrate emulsion for assay of lipoprotein lipase.

  1976cited by this paper

• Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia

  2025cites this paper
• Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.

  2025cites this paper
• Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

  2023cites this paper
• Effects of Administration of Recombinant Human Lecithin-Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans

  2023cites this paper
• Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

  2022cites this paper
• Fluorinated Benzyloxalamides: Glide Docking Pharmacophore Mapping Synthesis and In Vitro Evaluation as Potential Cholesteryl Ester Transfer Protein Inhibitors

  2022cites this paper
• Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

  2022cites this paper
• Can we revive CETP-inhibitors for the prevention of cardiovascular disease?

  2022cites this paper
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

  2021cites this paper
• Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

  2021cites this paper
• Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease

  2021cites this paper
• Lower LDL is better – can this be achieved with CETP inhibition therapy?

  2020cites this paper
• Cholesteryl Ester Transfer Protein and Lipid Metabolism and Cardiovascular Diseases.

  2020cites this paper
• Assessing the structure-function relationships of the apolipoprotein(a) kringle IV sub-type 10 domain

  2019cites this paper
• Trials and Tribulations of CETP Inhibitors.

  2018cites this paper
• Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain–Fused Anticalin Protein

  2018cites this paper
• Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

  2018cites this paper
• The metabolism of lipoprotein (a): an ever-evolving story

  2017cites this paper
• Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.

  2017cites this paper
• Drugs for rare disorders

  2017cites this paper
• Investigational therapies for hypercholesterolemia

  2017cites this paper
• Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

  2017influential citation
• Enhancing Studies of Pharmacodynamic Mechanisms via Measurements of Metabolic Flux: Fundamental Concepts and Guiding Principles for Using Stable Isotope Tracers

  2017influential citation
• Anacetrapib as a potential cardioprotective strategy

  2017cites this paper
• A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

  2017cites this paper
• CETP Deficiency and Concerns in CETP Inhibitor Development

  2017cites this paper
• The development of CETP (cholesteryl Trials and Tribulations of CETP Inhibitors

  2017cites this paper
• Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S]

  2017influential citation
• Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism

  2016cites this paper
• Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol

  2016cites this paper
• Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

  2016cites this paper
• Current and future trends in the lipid lowering therapy

  2016cites this paper
• Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.

  2016cites this paper
• Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

  2016cites this paper
• Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

  2016cites this paper
• Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Increases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

  2016cites this paper
• Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

  2016influential citation
• New Era of Lipid-Lowering Drugs

  2016cites this paper
• Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation

  2016cites this paper
• The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?

  2016cites this paper
• New oral agents for treating dyslipidemia

  2016cites this paper
• Cholesteryl ester transfer protein inhibitors: challenges and perspectives

  2016cites this paper
• Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

  2016cites this paper
• Personalized Proteomics: The Future of Precision Medicine

  2016cites this paper
• Personalized Proteomics: The Future of Precision Medicine.

  2016cites this paper
• The clinical utility of mass spectrometry based protein assays.

  2016cites this paper
• CETP Inhibition: Past Failures and Future Hopes

  2016cites this paper
• Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice[S]

  2016cites this paper
• Mass spectrometry meets the challenge of understanding the complexity of the lipoproteome: recent findings regarding proteins involved in dyslipidemia and cardiovascular disease

  2015cites this paper
• What does the future hold for cholesteryl ester transfer protein inhibition?

  2015cites this paper
• New Approaches in Detection and Treatment of Familial Hypercholesterolemia

  2015cites this paper
• Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?1

  2015cites this paper
• Changes in circulating proprotein convertase subtilisin / kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

  year unknowncites this paper
• Arteriosclerosis, Thrombosis, and Vascular Biology

  year unknowncites this paper